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Abstract
Background: Accurate diagnostic and monitoring tools for ulcerative colitis (UC) are missing. Our aim was to
describe the proteomic profile of UC and search for markers associated with disease exacerbation. Therefore, we
aimed to characterize specific proteins associated with inflamed colon mucosa from patients with acute UC using
mass spectrometry-based proteomic analysis.
Methods: Biopsies were sampled from rectum, sigmoid colon and left colonic flexure from twenty patients with
active proctosigmoiditis and from four healthy controls for proteomics and histology. Proteomic profiles of
whole colonic biopsies were characterized using 2D-gel electrophoresis, and peptide mass fingerprinting using
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was applied for
identification of differently expressed protein spots.
Results: A total of 597 spots were annotated by image analysis and 222 of these had a statistically different protein
level between inflamed and non-inflamed tissue in the patient group. Principal component analysis clearly grouped
non-inflamed samples separately from the inflamed samples indicating that the proteomic signature of colon
mucosa with acute UC is strong. Totally, 43 individual protein spots were identified, including proteins involved in
energy metabolism (triosephosphate isomerase, glycerol-3-phosphate-dehydrogenase, alpha enolase and L-lactate
dehydrogenase B-chain) and in oxidative stress (superoxide dismutase, thioredoxins and selenium binding protein).
Conclusions: A distinct proteomic profile of inflamed tissue in UC patients was found. Specific proteins involved in
energy metabolism and oxidative stress were identified as potential candidate markers for UC.
Keywords: Inflammatory bowel disease, Ulcerative colitis, Colon biopsies, Candidate markers, MS-based proteomics
Background
Ulcerative colitis (UC) is a chronic relapsing inflamma-
tory disease of the colon. Together with Crohn´s disease
(CD), UC is referred to as chronic inflammatory bowel
diseases (IBD). In Denmark, the incidence of UC is ap-
proximately 10 per 100,000 [1]. The underlying path-
ology of the disorder is complex and far from fully
understood [2-7].
High throughput technologies like microarray and
proteomic approaches can be utilized to identify disease
markers, which can be used for diagnostic and monitor-
ing purpose [8-12]. Based on these technologies several
candidate markers being correlated with IBD disease
phenotypes have been revealed, mainly identified from
serum samples [13-17], but also from colon tissues
[18-22]. Recently, biopsies from IBD patients were suc-
cessfully examined in a multigene analysis resulting in
diagnostic precision of IBD [18]. Thus, seven marker genes
were identified, where expression in colonic mucosal biopsies
differed between patients with UC, patients with CD and
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patients with non-IBD. Moreover, by the use of these marker
genes, the authors were able to distinguish between 38
patients with UC, 28 patients with CD and 20 patients with
non-IBD in a prospective panel [18].
Fecal calprotectin is a very sensitive marker for intes-
tinal inflammation, but it is not a specific marker and
increased levels are also found in neoplasia, infections,
polyps, and with use of non-steroidal anti-inflammatory
drugs and increasing age [23]. Thus, intestinal tissue
samples are suggested to be the most important source
for the identification of disease markers for further
validation [24].
Markers may serve a wide range of purposes in IBD,
such as diagnostic purposes, providing objective mea-
sures for disease activity, and as indicators for treatment
outcome. Thus, a panel of markers is needed to cover
these various clinical settings. For example the symp-
toms of IBD are often unspecific, and diagnosis may be
delayed with devastating impact on disease progression
as a result [25]. Therefore, fast and reliable diagnostic
tools are wanted [26].
During UC inflammation both the mucosa and sub-
mucosa will be affected, resulting in tissue damage
and ulceration, and studies based on whole biopsies
can thus be challenging due to tissue complexity.
However, routine endoscopic evaluations enable easy
examination of whole biopsies. With this in mind,
proteomics is an ideal hypothesis-free approach to
shed light on molecular characterization and diagnos-
tics of intestinal inflammation [24].
The aim of this study was to apply a comparative
proteomic approach in order to characterize the prote-
omic signature of inflamed versus non-inflamed colonic
tissue from twenty UC patients in order to establish a
baseline of markers, which are associated with active
UC. This is the first study analysing the global proteomic
signature of affected and non-affected colon tissues from
more than a few UC patients using 2-dimensional gel
electrophoresis (2-DGE) based proteomics coupled with
mass spectrometry (MS). We found 222 protein spots
which were significantly different expressed in inflamed
versus non-inflamed tissue. Of these, 43 protein spots
were identified and assigned to 33 individual proteins.
Methods
Patients and controls
Twenty patients (1:1 female–male ratio, mean age 40
(aged 18–67), 12 non-smokers, 7 former smokers and 1
current smoker) with proctosigmoiditis were recruited
from Viborg Regional Hospital, Denmark. Diagnosis of
proctosigmoiditis was based on clinical, endoscopic, and
histological examinations [27]. Of these, four patients
were diagnosed with UC for the first time at the endos-
copy. Among the 20 patients, ten were treated with 5-
aminosalicylic acid, (5-ASA) one with salazopyrine, one
with a diuretic and renin-angiotensin inhibitor due to
arterial hypertension, and eight were without daily
treatment. In addition, four voluntary healthy controls
(1:1 female–male ratio, mean age 32 (aged 18–50)) with-
out any familial disposition for inflammatory bowel
disease, daily medication, or any known diseases were
recruited by announcement. They were all without in-
flammation at the endoscopy.
Sample collection
Biopsies (3–10 mg) from patients and healthy con-
trols were sampled by endoscopy conducted at the
Medical Department at Viborg Regional Hospital,
Denmark. All study subjects fasted 12 h prior to en-
doscopy. Samples were taken for both proteomics and
histological analyses from each location. From the
healthy controls replicate biopsies (two for proteo-
mics, two for histology) were sampled from rectum
(RE), sigmoid colon (SI) and left colonic flexure (LF),
respectively, while, from patients, replicate biopsies
(two for proteomics, two for histology) were sampled
from acutely inflamed mucosa from RE (affected sam-
ple) or from non-inflamed mucosa from LF (control
sample), respectively. Biopsy specimens were immedi-
ately stored in dry ice and subsequently stored at
−80°C until preparation for 2-DGE.
Histological evaluation
The histological examination of inflamed, non-inflamed
and normal tissue was conducted on specimens taken in
the same area as those used for proteomic profiling and
fully agreed with the clinical assessment. The excised bi-
opsies were evaluated by a trained pathologist using
hematoxylin and eosin staining. The pathologist was
blinded for the clinical evaluation of the patients and the
proteomic results. The specimens were evaluated by con-
ventional histological criteria, including crypt distortion,
goblet cell loss, inflammation in the mucosal lamina pro-
pria, subcryptal leukocyte infiltration and absence of
changes specific for other diseases such as granulomas
[28,29]. Furthermore, the biopsies were graded using a
simplified method for histological assessment of inflam-
mation in UC [28], which includes crypt distortion (score
0–4), crypt inflammation (score 0–3) and subcryptal
leukocyte infiltration (score 0–2) (maximum score was 7).
Biopsy score from the healthy persons were 0 (25%-75%
percentiles 0–0) for biopsies from left colonic flexure, sig-
moid colon and rectum. Biopsy score from the patients
were median 0 (25%-75% percentiles 0–1) from left co-
lonic flexure and median 5 (25%-75% percentiles 4–5)
from rectum.
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Sample preparation and gel electrophoresis
Prior to 2-DGE whole mucosal biopsies were homoge-
nized and lysed in buffer (1 mg biopsy/10 μl lysis buffer)
consisting of 7 M urea, 2 M thiourea, 1.5% (wt/vol)
pharmalyte (pH 3–10, GE Healthcare, Uppsala, Sweden),
0.8% (wt/vol) 3-[(3-chol-amidpropyl) dimethylammonium]-
1-propansulfonate, CHAPS (Applichem, Darmstadt,
Germany) and 1% (wt/vol) dithioerythritol in water. After
2 h incubation at room temperature, lysed cells were centri-
fuged for 20 min at 10,000× g at 4°C, and the supernatant
was aspirated. Total protein content was determined by
BCA protein assay (BioRad), and 100 μg extracted protein
from individual biopsies were subsequently separated using
2-DGE with proteins initially being separated in the first di-
mension according to isoelectric focusing using immobi-
lized pH-gradient IPG strips (pH 5 to 8, 11 cm, BioRad,
Hercules, CA). In order to achieve optimal focusing and
gradient flow, the running conditions were 5 h at 200 V, 3 h
at 500 V and 16 h at 3500 V. Hereafter, 12.5% sodium dode-
cyl sulphate polyacrylamide (SDS-PAGE) Criterion gels
(BioRad) were used for second dimension separation with
proteins running for 1 h at 200 V. For visualization of pro-
tein spots analytical gels were stained with Flamingo Pink
(BioRad), and scanned at appropriate wavelength for fluor-
escence images (FX Pro Fluorescent Scanner, BioRad).
Image analysis
Gel images were processed and gel spots detected and
quantified with Progenesis SameSpot (version 3.3, Non-
linear dynamics, Newcastle, UK). Initially a few anchor
spots were manually defined and followed by the build-
in automated alignment procedure. Spot border lines
were created from a selected reference gel and applied
to all gels. After background subtraction, a gel to gel
normalization based on a logarithmic abundance ratio of
the spot volumes was performed in order to minimize
bias from e.g. pipetting errors, when loading sample, or
inconsistency in the transfer of proteins from the first to
the second dimension. The output dataset contained no
missing values since all spot areas were present, and
quantified in all gels. The resulting normalized spot
volumes were subsequently analyzed in order to identify
spots with different protein expression between groups.
In-gel digestion and peptide mass fingerprinting
For peptide mass fingerprinting (PMF) proteins of inter-
est were subjected to in-gel digestion by addition of
trypsin using an in-gel protocol, essentially as described
by Jensen et al. [30]. Custom-made chromatographic
columns were used for desalting and concentration of
the peptide mixture prior to MS analysis [31]. Hereafter,
peptides were eluted in 0.5 μL of matrix solution (15–
20 g/L of α-cyano-4-hydroxycinnamic acid; Sigma
Aldrich, St. Louis, USA, in 70% acetonitrile) directly
onto the MALDI target plate (Bruker Daltonics GmbH,
Bremen, Germany). Mass spectra were obtained using
an Ultraflex MALDI-TOF tandem mass spectrometer in
reflection mode (Bruker Daltonics, Bremen, Germany).
A peptide calibration standard ranging from 1046.54 to
3147.47 g/mol was spotted separately onto the MALDI
target plate. The ion-accelerating voltage was 25 kV and
the laser frequency of 50 Hz with 200 laser spots accu-
mulated for each spectrum. For tandem mass spectrom-
etry (MS/MS, lift mode), the ion accelerating voltage
was 19 kV, and the protein was identified based on the
Mascot scores of the peptide subjected to MS/MS
analysis.
Data analysis
In order to identify spots with significantly different pro-
tein levels in the inflamed versus non-flamed mucosa of
UC patients, we applied a one-way analysis of variance
(t-test) using the logarithm of the normalized spot
volumes. A false discovery rate (FDR), the proportion of
significant features that turn out to be false due to mul-
tiple testing was calculated as q-value [32]. We also ap-
plied multivariate statistics, which is ideal for 2-DGE
datasets typically consisting of long and lean data with
relatively few observations (samples) and many variables
(protein spots). The normalized spot volumes were
imported into SIMCA 9.0 (Umetrics), and preprocessed
with mean centering. For principal component analysis
(PCA) of proteomic data from control persons, data was
autoscaled, while group scaling was considered to be a
more optimal scaling approach for PCA of proteomic
data from patients. While autoscaling is based on overall
standard deviation, group scaling is based upon the
within-group standard deviation, and therefore gives a
higher weight to the group-dependent proteins [33].
PMF mass searches were conducted in the Mascot
ions search engine (Matrix Science, Boston, USA) using
the Swiss-Prot database (Swiss Institute of Bioinformat-
ics, Geneva, Switzerland). The Mascot software uses a
scoring algorithm to identify the closest match and signifi-
cant protein identification. The ions score is −10*Log(P),
where P is the probability, that the observed match is a
random event. In this study a protein score having a sig-
nificance level of P < 0.05 indicated identity or extensive
homology. For MS/MS identification, fragmentation of the
parent ion was followed by mass searches in the database.
Ethical considerations
All subjects received written and oral information and
gave written informed consent. The study was done in
accordance with the Declaration of Helsinki and was
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approved by the Danish Regional Ethics Committee (VN
20060041).
Results
Proteomic profiles of control persons and UC patients
The initial proteomic survey carried out on control per-
sons indicated that the individual protein level between
different locations in normal colon mucosa was not
prominent, since the PCA score plot of proteomic data
from control persons demonstrated a grouping accord-
ing to individuals and not to specific colon positions
(Figure 1). The systematic variation was more related to
individual variation, than to variation between colon
positions, though the first two components explain only
23% of the variation in the dataset.
The protein composition of biopsies from UC patients
differed in the non-inflamed versus inflamed mucosa.
After manual gel inspection of spot alignment, the image
analysis annotated a total of 597 spots. Statistical signifi-
cance (P < 0.05) was achieved for 222 spots being
differentially expressed in inflamed versus non-inflamed
mucosa, and of these 39 spots were highly significant
(P < 0.0001). After correction for multiple testing by
FDR, the proportion of significant spots estimated to be
false positives were 4.1% for a statistical significance
level of 0.05 (q = 0.041) and 0.05% for a statistical signifi-
cance level of 0.0001 (q = 0.0005).
PCA of the proteomic profiles of biopsies from UC
patients grouped control samples from left colonic flex-
ure separately and away from inflamed rectum tissue,
with the two first components explaining 33% of the
variation (Figure 2). In spite of this apparent grouping of
specific mucosa, it was also evident that some of the
inflamed patient biopsies did not seem to exhibit an
inflamed profile (RE biopsy from patient 21 and 35), and
accordingly grouped with LF biopsies. Moreover, the LF
biopsy from patient 20 resembled that of RE biopsies
more than LF biopsies. Since our histopathological
examination did not support outlier status of these biop-
sies, we have not excluded these patients, but ascribed it
Figure 1 Principal component analysis of the proteomic profiles of healthy control persons. Results are based on 2-DGE spot volumes.
Replicate biopsies were analysed from rectum (RE), sigmoid colon (SI) and left colonic flexure (LF). Control person 1 (+), control person 2 (■),
control person 3 (♦) and control person 4 (▲).
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to natural variation within the biological material. Fur-
thermore, there was no apparent grouping of the ten
patients treated with 5-ASA (data not shown) and the
patient group was therefore evaluated as one group.
Twenty statistically significant protein spots showed
more than twofold increase or decrease in protein level
when comparing inflamed and non-inflamed patient tis-
sue, and these spots were all manually dissected and
trypsinated for further MS identification. In total 14 of
the protein spots were identified using MALDI-TOF MS
analysis (Table 1), and a more than twofold difference in
protein level was thus observed for glycerol-3-phosphate-
dehydrogenase (2 hits), B-cell antigen receptor complex-
associated protein beta chain, annexin A6, plasma-cell
induced resident endoplasmatic reticulum protein, cyto-
plasmic actin, alpha enolase (2 hits), L-lactate dehydrogen-
ase B-chain, tubulin beta 5-chain hydroxymethylglutaryl
CoA synthase, selenium binding protein (2 hits) and
carbonic anhydrase 2. Of these spots glycerol-3-phosphate-
dehydrogenase showed the highest (3.3 fold) and alpha-
enolase (spot 10) the lowest level (3.7 fold) in the inflamed
tissue compared to the non-inflamed tissue. All except one
(B-cell antigen receptor complex-associated protein, beta
chain) of the identified spots had significant Mascot scores
and the statistical significance of the spots was generally
strong.
Twenty-nine additional spots were successfully identi-
fied (Table 2). Several of these had strong statistical
Figure 2 Principal component analysis of the proteomic profiles of UC patients. The results are based on results from 2-DGE spot volumes.
Biopsies were from rectum (RE) and left colonic flexure (LF). LF (▲) and RE (■).
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support for a different protein level, while others were
spots with high spot volumes and therefore suitable for
MALDI-TOF identification. Annexin A1 (spot 35) was
the only spot not having a significant Mascot score for
protein identification. MS/MS was performed on two
protein spots resulting in positive identification of
glycerol-3-phosphate-dehydrogenase (spot 1) and serum
albumin (spot 23).
Changes in proteomic signatures in control persons
versus UC patients
In order to assess whether spots showing different pro-
tein level within UC patients could be supported by in-
formation from the control persons, the identified spots
were examined in RE and LF from both control persons
and UC patients. In this way, protein spots that merely
reflected position effects (i.e. showing the same differ-
ence in the control group) or nonsense patterns (e.g.
when the control group resemble patient RE) rather than
distinct inflammation profiles could be evaluated. Using
this approach five of the identified spots (alpha-enolase
(spot 10 and spot 43), hydroxymethylglutaryl–CoA syn-
thase, cathepsin D and 60 kDa heat shock protein) did
not qualify for candidate marker. Alpha-enolase (spot
10) and hydroxymethylglutaryl–CoA synthase both had
a significantly different protein level in the control biop-
sies as well as in the patient biopsies when comparing
RE and LF, and showed a similar pattern in both groups
that could indicate that these proteins were rather
position markers than disease markers. Regarding alpha-
enolase (spot 43), cathepsin D and 60 kDa heat shock
protein, the protein levels in the inflamed mucosa (RE)
were similar to RE and LF level from control persons.
Candidate markers and affected biological pathways
The 43 protein spots identified was assigned to 33 individ-
ual proteins, since more than one isoform were recognized
for several of the proteins. The high level of glycerol-3-
phosphate-dehydrogenase (spot 1 and spot 4) in the
inflamed mucosa of patients compared to non-inflamed
mucosa was highly significant (Figure 3). Likewise, several
isoforms of selenium binding protein were identified, but
all found to have low protein levels in inflamed mucosa
compared to non-inflamed tissue. In general, the proteins
identified could be assigned to biological pathways such as
energy metabolism, response to oxidative stress and
stress-response mechanisms (Table 3).
Discussion
In this study samples from both inflamed and non-
inflamed tissues from each patient were analyzed. The
histological assessment of the biopsies confirmed that
the patient biopsy from the left colonic flexure could be
assessed as non-inflamed and did not show any signs of
sub-inflammation. This is the first study to assess a rela-
tively high number of UC patients using this approach
and in spite of large individual heterogeneity we found
statistical support for tissue specific levels of many
Table 1 List of significant proteins showing more than twofold altered protein expression within UC patients
Spot Protein Name SwissProt Acc. no. S cov %1 pI2 Mw2 Fold diff.3 T-test (p)4
Higher level in RE
1 Glycerol-3-phosphate-dehydrogenase P04406 6a 9.3 36 3.30 1.388e-005
25 B-cell antigen receptor complex-associated protein beta chain P40259 42 5.6 26 3.05 3.776e-004
3 Annexin A6 P08133 41a 5.3 76 2.81 1.626e-006
4 Glycerol-3-phosphate-dehydrogenase P04406 37a 9.3 36 2.70 6.178e-005
5 Plasma-cell induced resident endoplasmatic reticulum protein Q8WU39 52a 5.3 21 2.61 4.785e-005
65 Actin cytoplasmic P60709 42a 5.5 41 2.45 1.049e-006
7 Alpha enolase P06733 35a 7.7 47 2.42 5,889e-005
8 L-lactate dehydrogenase B-chain P07195 46a 5.7 37 2.40 4.021e-005
9 Tubulin beta 5-chain P07437 41a 4.6 50 2.18 1.801e-004
Lower level in RE
10 Alpha-enolase P06733 44a 7.7 47 3.70 1.403e-008
11 Hydroxymethylglutaryl–CoA synthase P54868 28a 9.2 57 2.94 2.448e-009
12 Selenium binding protein Q13228 42a 5.9 53 2.50 3.770e-007
13 Carbonic anhydrase 2 P00918 60a 7.0 29 2.33 8.325e-007
14 Selenium binding protein Q13228 60a 5.9 53 2.08 5.508e-006
1Percentage sequence coverage (S cov %) is followed by a if the mascot score was significant (P < 0.05). 2Isoelectric point (pI) and molecular weight (Mw) are
presented as theoretical values. 3Fold difference in protein level. 4p-value from t-test. 5Spot location on the gel differs from the theoretical molecular mass. 6The
protein was identified by MS/MS.
Poulsen et al. BMC Gastroenterology 2012, 12:76 Page 6 of 11
http://www.biomedcentral.com/1471-230X/12/76
proteins being associated with disease exacerbation. Re-
cently, proteomic studies have contributed with promis-
ing candidate markers being correlated with disease
phenotypes, either in IBD patients in general, specifically
within UC patients or between UC, CD and control per-
sons [20-22].
In this study, the spots characterized by a larger than
twofold difference in protein level were classified as the
most promising markers. These spots together with the
additional spots identified included proteins already known
to be associated with inflammation states of IBD (e.g. trio-
sephosphate isomerase, alpha enolase, selenium binding
protein, superoxide dismutase, thioredoxin-dependent per-
oxide reductase, Hsp60, Hsp70) [19,22,34], as well as novel
proteins (e.g. glycerol-3-phosphate-dehydrogenase, isoci-
trate dehydrogenase, L-lactate dehydrogenase B-chain,
inorganic pyrophosphatase, enoyl-CoA hydratase, peroxire-
doxin-4, peroxiredoxin-6), where the association with UC
and inflammation needs replication. Integration of excised
biopsies from control persons was used to strengthen our
conclusions, since protein spots showing different protein
levels between RE and LF colon mucosa of control persons
could be excluded as merely position specific markers, and
not disease markers. Furthermore, there is a strong support
Table 2 List of additional significant proteins identified in UC patients
Spot Protein Name SwissProt Acc.no. S cov %1 pI2 Mw2 Fold diff.3 T-test (p)4
Higher level in RE
15 Superoxide dismutase P04179 61a 7.0 22 1.9 1.076e-007
16 Peroxiredoxin-4 Q13162 59a 5.8 31 1.7 1.510e-006
17 F-actin capping protein subunit alpha-1 P52907 44a 5.5 33 1.6 8.491e-005
18 Inorganic Pyrophosphatase Q15181 48a 5.5 33 1.4 1.461e-004
19 Triosephosphate isomerase P60174 48a 7.7 27 2.0 3.173e-004
20 Actin cytoplasmic P60709 62a 5.2 42 1.8 5.368e-004
21 Thiosulfate sulfurtransferase Q16762 49a 6.9 34 1.3 0.004
22 Serum albumin P02768 16a 5.9 71 1.4 0.005
23 Serum albumin P02768 5a 5.9 71 1.8 0.005
24 Proteasome activator Q9UL46 53a 5.4 28 1.2 0.005
25 Serotransferrin P02787 24a 7.0 79 1.4 0.014
26 F-actin capping protein subunit beta P47756 45a 5.6 31 1.1 0.025
Lower level in RE
27 Selenium binding protein Q13228 60a 5.9 53 1.4 1.525e-006
28 Protein ETHE1 O95571 56a 6.4 28 1.4 2.911e-006
29 Enoyl-CoA hydratase P30084 46a 9.4 32 1.3 7.862e-006
30 Isocitrate dehydrogenase O75874 35a 6.6 47 1.7 9.730e-006
31 Elongation factor Tu P49411 52a 7.9 50 1.4 2.055e-005
32 Peroxiredoxin-6 P30041 63a 6.0 25 1.4 8.820e-005
33 Tubulin alpha-6 chain Q9BQE3 29a 4.8 50 4.100e-005
34 Carbonic anhydrase 1 P00915 46a 6.7 29 2.0 1.354e-004
35 Annexin A1 P04083 34 6.7 39 1.3 2.942e-004
36 Cathepsin D P07339 33a 6.1 45 1.3 3.062e-004
37 Thioredoxin-dependent peroxide reductase P30048 55a 8.9 28 1.3 0.001
38 Heat shock protein 70 kDa /Serum albumin P08107/P02768 33a/66a 5.9/5.4 70/71 1.4 0.004
39 60 kDa heat shock protein P10809 41a 5.6 61 1.3 0.014
40 Serum albumin P02768 18a 5.9 71 1.3 0.019
41 Triosephosphate isomerase P60174 63a 6.5 27 1.3 0.019
42 Serum albumin P02768 20a 5.9 71 1.3 0.021
43 Alpha-enolase P06733 42a 7.7 47 1.1 0.042
1Percentage sequence coverage (S cov %) is followed by a if the mascot score was significant (P < 0.05). 2Theoretical isoelectric point (pI) and theoretical molecular
weight (Mw) are presented. 3Fold difference in protein level. 4p-value from t-test. 5The protein was identified by MS/MS.
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for regarding our significant spots as true positives since
only nine false positives are expected out of 222 spots
(q=0.041), and only 0.02 spot out of the 39 highly signifi-
cant (q=0.0005).
The proteomic profile of the inflamed tissue was very
distinct with 37% of the annotated protein spots having
significantly different protein levels when comparing
inflamed and non-inflamed patient mucosa. Focusing on
the spots found to have at least more than twofold dif-
ference in protein level between patient biopsies, 70%
(14 spots out of 20 possible) were successfully identified.
Further identification of additional protein spots with
strong statistical support strengthened the overall under-
standing of how inflammation changes the proteomic
signature of UC patient colon biopsies. We found that,
apart from the highly abundant proteins like serum albu-
min and cytoplasmic actin, excised spots could primarily
be assigned to proteins involved in stress response
mechanisms and energy metabolism. Different levels of
these proteins could infer that acute inflammation in UC
patients in particular impair and affect regulation of
these biological processes.
Different protein profiles of several glycolytic enzymes
(triosephosphate isomerase, glycerol-3-phosphate-de-
hydrogenase, alpha enolase) and other proteins involved
in energy generation (isocitrate dehydrogenase, L-lactate
dehydrogenase B-chain, inorganic pyrophosphatase,
enoyl-CoA hydratase) could indicate inflammation asso-
ciated alterations in energy metabolism in UC patients.
This could be due to malfunction of the utilization of n-
butyrate, which is the preferred fuel for colonocytes in
the distal colon [36]. The observed lowered enoyl-CoA
hydratase in inflamed tissue infer impaired fatty acid
oxidation and the energy-deficiency is further strength-
ened by change in the glycolytic pathway reflected as a
higher expression of glycolytic enzymes in inflamed mu-
cosa. In accordance with the present findings, Hsieh
et al. [22] observed a down-regulation of triosephosphate
isomerase in UC-diseased colon mucosa, while Nanni
et al. [35] observed an up-regulation of the same enzyme
Figure 3 Different protein level in rectum and left colonic flexure from control persons and UC patients. (A) Glycerol-3-phosphate-
dehydrogenase (spot 1) and (B) Glycerol-3-phosphate-dehydrogenase (spot 4). Representative 2-DGE images from the four groups and
normalised protein expression of the same groups presented as mean± standard error. Control persons (REC and LFC) and UC patients (REP and
LFP).
Table 3 Biological processes associated with identified proteins with references to results obtained in earlier studies
Biological process Protein name
Energy generation triosephosphate isomerase1,3,4, glycerol-3-phosphate-dehydrogenase, alpha enolase2,3, isocitrate dehydrogenase,
L-lactate dehydrogenase B-chain, inorganic pyrophosphatase, enoyl-CoA hydratase
Response to oxidative stress selenium binding protein1,2, superoxide dismutase, thioredoxin-dependent peroxide reductase1, peroxiredoxin-14,
peroxiredoxin-4, peroxiredoxin-6
Stress response proteins Alpha-enolase3, Hsp601,3, Hsp701,4
1Different protein level between diseased UC versus normal colon mucosa tissues using colon biopsies [22]. 2Different protein level between inflamed and non-
inflamed tissue regions in single UC patients as identified in purified epithelial cells from biopsies [19]. 3Different protein level in mucosal tissue biopsies from
patients with chronic refractory pouchitis before and after antibiotic/probiotic therapy [34]. 4Different protein level between intestinal epithelial cells from healthy
subjects and CD patients [35].
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in intestinal epithelial cells from CD patients. In
addition, a changed regulation of alpha-enolase has been
associated with IBD [37], which has been suggested to
reflect anaerobic glycolysis in UC patients with inflamed
pouch [34]. However, changes in the level of alpha-
enolase could also reflect non-glycolytic mechanisms,
since the protein is also induced as a heat shock protein
under hypoxic stress [38]. Induced expression of heat
shock proteins due to cellular stress would probably be
expected in IBD patients [39-41] and is further reflected
in the lower expression of 60 and 70 kDa heat shock
proteins observed in inflamed tissue.
Inflammation in IBD patients generally increases the
level of reactive oxygen metabolites resulting in oxidative
stress due to an imbalance between antioxidants and re-
active oxygen [42,43]. Different levels of several antioxi-
dant proteins (selenium binding protein, superoxide
dismutase, thioredoxin-dependent peroxide reductase,
peroxiredoxin-4 and peroxiredoxin-6) suggest an in-
creased level of oxidative stress in UC patients, and earl-
ier studies have specifically documented a regulation of
selenium-binding protein and superperoxide dismutase
in relation to patients with IBD [26,44-46]. Impaired oxi-
dative metabolism and affected antioxidant defenses thus
seem to play an important role in the pathogenesis of
IBD diseases, and changed expression of involved protein
is most likely related to a stimulated cell activity
(e.g. neutrophils) due to severe inflammation.
Generally, the control persons demonstrated a high
variability among individuals reflecting an individual
protein signature rather than a strong position specific
proteomic profile of biopsies excised from the same
bowel location in different individuals. However, some
proteins were still found to be significantly differently
expressed between RE and LF tissues, indicating that
these could be assigned as position markers. Two of the
spots found to represent very different protein levels
within the UC patients fell into this category (α-enolase
(spot 10) and hydroxymethyl glutaryl-CoA synthase).
These proteins could falsely have been ascribed as good
candidates for disease markers if the control persons
were not taken into account. Regardless of the need for
control persons in terms of validation of markers as ac-
tual disease markers, and not just position markers, in-
ternal controls within the same patient seems to be a
robust and more simplistic approach to implement.
Here, the control persons were healthy, while in other
studies, controls have been patients with e.g. colorectal
carcinoma [19,45], which could complicate the interpret-
ation of results, since UC and colorectal carcinoma are
closely linked conditions, and even tumor free tissue
from cancer patients could deviate from normal tissue
[47]. We have not addressed the individual variation in
protein level between patients, which could be
substantial [19], but instead focused on protein spots
having robust signatures across patients.
Overall, 2-DGE analysis has improved in relation to
reproducibility, repeatability and better image analysis,
and in this study the limitation related to PMF using
MALDI-TOF MS technology, was due to the quantity of
the protein spots and sensitivity of the instrument,
which played a major role for successful protein identifi-
cation. Despite its flaws, MS-based proteomic techni-
ques are efficient in providing new insights into
pathogenesis of diseases not only through identification
of involved proteins but also for potential effects of dif-
ferent isoforms, like post-translational modifications
[48]. We observed several individual proteins being
assigned to multiple spots (e.g. alpha-enolase), but the
underlying modifications were not studied further. Some
proteins with horizontal patterns could for instance, in-
dicate phosphorylations, changing the charge of proteins
as observed in the train of protein spots assigned to
selenium binding protein.
Protein extraction from whole colonic biopsies as con-
ducted here means that a long and tedious procedure
for isolation of e.g. intestinal epithelial cells is avoided.
On the other hand the proteomic profile from diverse
cell types of both intestinal and immune origin could
potentially result in larger variability between the sam-
ples and a limited control of cell specific signatures, with
a risk of some cell types overruling important expression
patterns of others [8]. Essentially, whole biopsies from
IBD patients contain multiple populations of cells, in-
cluding inflammatory cells, and thereby proteins identi-
fied could potentially reflect other mechanisms resulting
from i.e. cell death or serum. To avoid introduction of
sources of errors whole biopsies is preferred for clinical
use. Our study thus resembles the clinical setting in this
respect. Precautions in relation to collection, processing
and storage should be taken seriously for minimizing
factors that potentially could alter the molecular com-
position of the tissue material [49]. Here, the biopsies
were stored immediately on dry ice after collection and
subsequently on −80°C, which in combination with gen-
tle handlings throughout all analyses ensure a high qual-
ity of the collected material.
The patients in the UC cohort included in this study
received different medical treatments, which potential
could affect their protein profiles. Based on the PCA
plot, the variation among the patient group treated with
5-ASA was, however, not different from the remaining
patients, and therefore it was not evident that the treat-
ment had a strong effect on the proteomic signature of
the analyzed biopsies.
In conclusion, we have generated insights into the
underlying mechanisms of active UC. The overall prote-
omic signature of inflamed colon mucosa was strong.
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Such assessment of biopsies from the active site of the
disease reveal protein markers associated with inflamed
tissue, and could be an important entry point for the dis-
covery of new and improved non-invasive markers [24].
Thus, future studies further addressing the marker pro-
teins found are essential for evaluation of disease specifi-
city and clinical relevance.
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